Skip to main content
Back to feed
HealthConfirmedMediumDeveloping
6.7

FDA disputes Capricor Phase 3 trial results for Duchenne muscular dystrophy treatment

The FDA has formally stated that Capricor's stem cell therapy for Duchenne muscular dystrophy failed to meet primary Phase 3 trial objectives. This assessment directly contradicts the company's previous public claims, creating significant regulatory uncertainty for the drug's approval pathway.

STAT Newsabout 8 hours agoUSCredibility 27%View source

Score Breakdown

Mosaic Score6.7
Confidence0.9
Significance0.5
Source credibility0.3

Intelligence Tags

#fda#biotech#clinical-trials#duchenne#capricor

Entities

country
Source

Related signals

8 found